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Abstract 
ABSTRACT 
Review on Acute promyelocytic leukemia, with data 
on clinics and the genes involved. 
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Identity 
Note 
FAB criteria AML M3 
 at least 20% of bone marrow cells are abnormal 
promyelocytes, with a characteristic pattern of heavy 
granulation 
 characteristic cells contain bundles of Auer rods 
("faggots") 
FAB criteria AML M3v 
 As other AML, at least 20% of bone marrow cells 
are blast cells. Blast cells have minimal granulation, 
relative scarcity of cells with heavy granulation and 
cells containing multiple Auer rods. The nucleus of 
blast cells is bilobed, multilobed or reniform, but the 
majority of cells are either devoid of granules or 
contain only a few fine azurophil granules. However, 
at least a few cells with all the cytoplasmic features 
of typical AML M3 are present. If these are 
overlooked, the cases are likely misdiagnosed as 
monocytic leukemia. The M3v morphology is 
mainly a feature of the peripheral blood cells - bone 
marrow morphology is closer to that of typical AML 
M3. 
 both subtypes show a very strong myeloperoxidase 
reaction and a negative reaction for non-specific 
esterase. Exceptional APL PML/RARA cases with 
basophilic granulations, metachromatic with 
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toluidine blue, can be MPO negative (Invernizzi R et 
al , 1995).  
Immunophenotype  
 mature myeloid phenotype, characteristic but not 
diagnostic: 
 CD34 negative, HLA-DR negative, CD33 positive, 
CD13 positive. 
 Aberrant expression of CD56 is observed in 
approximately 10% of APL patients and is 
associated with a higher WBC count, a more 
frequent bcr3 isoform and, in some series of patients, 
a shorter event free survival (Testa and Lo-Coco, 
2016). 
 in M3 but not M3v: characteristic light scatter 
pattern, strong unspecific fluorescence signal 
WHO classification (2008, updated 2016)  
 APL with t(15;17)(q24;q21) PML/ RARA (WHO 
2008) is now reported as APL with PML/RARA  
(WHO 2016) 
 Other very rare AML M3/M3v harbouring recurring 
translocations involving RARA with variant genes 
other than PML previously mentioned as AML with 
variant partners of RARA (WHO 2008) should be 
reported accordingly: 
 AML with t(11;17)(q23;q21) 
ZBTB16/RARA (previously named 
PLZF/RARA), 
 AML with t(11;17)(q13;q21) 
NUMA1/RARA, 
 AML with t(5;17)(q35;q21) NPM1/RARA, 
 AML with der(17); STAT5B/RARA (either 
cryptic abnormality leading to normal 
chromosome 17 on karyotype or abnormal 
der(17) both due to complex rearrangements 
involving STAT5B located downstream to 
RARA on band 17q21.2 and oriented 5'-3' 
telomere to centromere  ). 
Clinics and pathology 
Disease 
Epidemiology 
Rare: 5 - 8 % of AML, incidence higher in Spain, 
Italy and Latinos; occurs at any age, predominantly 
adults in mid-life.  
Account for approximatively. 5% of treatment 
related leukemias (t-AML); 5-22% of APL are t-
APL, mostly after breast cancer treated by 
epirubicine or mitoxantrone (chemotherapy 
targeting topo 2 isomerase); short-delayed  (median 
inferior to 3 years) ; favorable prognosis among t-
AML:  benefit from ATRA-ATO treatment thus 
avoiding  anthracyclins (reviewed in Lo Coco F, 
2013). 
Clinics 
Low WBC in AML M3, high WBC in AML M3v; 
frequently associated with disseminated 
intravascular coagulation (DIC) and 
hyperfibrinolysis which are the main factors of 
immediate bad prognosis and death when diagnostic 
and treatment are delayed.  
Biological and clinical data favour a crucial role of 
the leukemic cells in the development of the 
coagulopathy which is a multifactorial event, 
involving DIC and primary hyperfibrinolysis 
(Mantha et al., 2016). 
Cytology 
The cytomorphology of APL blasts is obviously 
different in the two subtypes: in AML M3, the 
abnormal promyelocytes show a heavy granulation 
and bundles of Auer rods; in AML M3v blasts have 
a non- or hypogranular cytoplasm or contain fine 
dustlike cytoplasmic granules that may not be 
apparent by light microscopy. Furthermore, M3v 
blasts show a typical bilobed nuclear configuration. 
This latter morphologic phenotype, together with 
missing granulation, often resulted in the misleading 
diagnosis of acute monocytic or myelo-monocytic 
leukemia before the cytogenetic correlation of both 
AML M3 and M3v with t(15;17)(q24;q21) was 
observed. AML M3v accounts for approximately 1/3 
of APL cases. 
Treatment 
Previous chemotherapies which associated 
anthracyclines and cytosine arabinoside allowed 
long-lived remission in less than 50% of patients. 
From 1985 retinoic acid (RA) isomers were 
introduced with success as differentiation agents in 
several series of APL patients. The first molecule 
tested was 13-cis RA. In parallel all-trans RA 
(ATRA) showed a quite better efficacy. Then 
another molecule, arsenic trioxide (ATO), acting on 
differentiation and apoptosis, was tested with good 
results. With the current treatments, involving 
anthracycline chemotherapy associated with ATRA 
and/or ATO, a long-lived remission is obtained in 
more than 90% of cases, and bone marrow 
transplantation has been restricted to the sole cases 
of first relapse. Particularly the introduction of 
ATRA and/or ATO therapy at diagnosis, has largely 
reduced the rate of early death due to the 
coagulopathy associated with APL first stage (Wang 
Z-Y and Chen Z, 2008). Patients with low WBC (less 
than 10G/L) can be treated at diagnosis with ATRA 
and ATO thus avoiding the toxicity of chemotherapy 
especially anthracyclins (Lo Coco et al, NEJM, 
2013).  
To be noted that some variant translocations, i.e. 
t(11;17) with ZBTB1/RARA fusion and der(17) with 
STAT5B/RARA fusion do not respond to ATRA 
and ATO therapy, consequently their prognosis is 
quite more pejorative. 
Evolution 
APL PML/RARA have to be monitored by RQ-PCR 
on bone marrow samples  every 3 months after 
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diagnosis for 18 months as patients with molecular 
relapse can benefit from preemptive therapy . 
Patients with hyperleucocytosis at diagnosis ( more 
than 10 G/L WBC) or slow responding  to treatment 
more especially  benefit from this survey .(reviewed 
in Grimade D et al, BPRCH, 2014) 
Prognosis 
Adverse prognosis factors  
 High WB (more than 10 G/L). 
 The previously reported FLT3- internal tandem 
duplication (ITD).   
 Bad prognosis value is correlated with 
hyperleucocytosis asit is the case for the bcr3 
molecular breakpoint and the M3v form. 
 Bleeding episodes. 
Cytogenetics 
Cytogenetics morphological 
t(15;17)(q24.1;q21.2)  leading to a PML 
(promyelocytic leukaemia)/RARA(retinoic acid 
receptor α) on der(15) and RARA/PML  on der(17) 
rearrangements at the molecular level. 
Complex translocations involving one or more 
chromosomes in addition to 15 and 17 are found in 
2-5% of cases with PML/RARA rearrangement. 
Cytogenetically cryptic PML/RARA 
rearrangements are observed in 2-3% of APL cases. 
Cases lacking PML/RARA rearrangement account 
for less than 2% M3/M3v AML cases and mainly 
involve RARA with partner genes different from 
PML (Grimwade D et al, Blood 2000). 
Cytogenetics molecular 
When karyotype fails to give an informative 
response, either for absence or poor quality 
metaphases or in case of complex or cryptic 
rearrangement, FISH analysis may be useful to 
validate PML/RARA fusion and initiate without 
delay or maintain specific APL therapy.  
Furthermore as cytogenetic diagnosis is urgent, 
FISH analysis can be performed urgently in parallel 
with karyotype analysis, preferably on cultured and 
fixed cells.  
Among cryptic rearrangements, they are mainly 
insertions: 
 mainly insertion of 3'RARA into the PML gene: 
ins(15;17)(q24;q21q21) 
 but insertions of 5'PML into RARA can also be 
seen: ins(17;15)(q21;q24q24) 
Probes 
Different type of probes are commercially available: 
 PML/RARA fusion probes leading to either double 
or single fusion signals in positive cells 
 RARA break-apart probes leading to  separated 
5'RARA and 3'RARA signals signal in positive cells 
but failing to identify the RARA partner in nuclei. 
They identify the partner chromosome band if 
metaphases are present on the hybridized slide.  
Among these probes, some are less informative in 
case of cryptic insertions which accounts for 
approximately 5% of APL cases 
 Very large probes can fail to detect very small 
insertions. 
 RARA probes cannot detect PML insertions. 
 Flanking probes can fail to detect very small 
insertions. 
The choice of informative probes has to take into 
account the probe maps and the critical fusion gene 
to be detected (PML/RARA rather than 
RARA/PML), thus covering 5'PML and 3'RARA. In 
order to obtain an optimal diagnosis (rapid and 
informative) multiple slides, each with a different 
type of probe can be hybridized. Furthermore, small 
insertions are easier to be detected on metaphases 
rather than on nuclei and the chromosomal location 
of the specific signals is very helpful for diagnosis. 
Other diagnosis tools are:  
PML immunofluorescence leading to a specific 
microspeckled pattern in nuclei of PML/RARA 
positive cases, related to the disruption of PML 
nuclear bodies. 
PML/RARA RT-PCR analysis, very specific and 
sensitive, mandatory at diagnosis. 
Additional anomalies 
(ACA) are observed in 35-45% of cases at diagnosis 
(62% at relapse), most frequent: +8(or trisomy 8q), 
del(9q), ider(17)(q10)t(15;17) or del(17p)  
Classically, ACA do not impact the prognosis, 
however the loss of one copy of TP53 gene generated 
by ider(17q) or del(17p) could  have a prognostic 
value. Complex karyotype at diagnosis, defined as ≥ 
2 anomalies in addition to t(15;17), could be 
associated too with a reduced overall survival (Poiré 
X et al., 2014). 
Variants 
Approximately 1-2% of M3/M3v AML cases harbor  
a variant translocation which fuses RARA with an 
other partner gene than PML (Grimwade D et al. 
2000; Redner RL, 2002):  
 t(11;17)(q23;q21) ZBTB16/RARA (also named 
PLZF/RARA), is the most frequent 
 t(5;17)(q23;q21) NPM1/RARA, 
 t(11;17)(q13;q21) NUMA1/RARA, 
 der(17) STAT5B /RARA, 
 der(17) PRKAR1A /RARA, 
 t(X;17)(p11;q12) BCOR /RARA, 
 t(4;17)(q12;q21) FIP1L1 /RARA 
 t(1;17)(p34;q21) IRF2BP2 /RARA 
 t(2;17)(q32;q21) NABP1 /RARA 
 t(3;17)(q26;q21) TBL1XR1 /RARA 
 t(7;17)(q11;q21) GTF2I /RARA 
The cases with variant translocation have initially 
been reported as having APL morphology. However, 
morphological differences exist. Clinically 
important is that APL variant with t(5;17)(q12;q12) 
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NPM1/RARA, respond to ATRA, while M3/M3v 
AML  with t(11;17)(q23;q12) ZBTB16/RARA or 
der(17) STAT5B/RARA do not respond to ATRA or 
ATO. 
Genes involved and 
proteins 
PML (promyelocytic leukemia) 
Location 
15q24.1 
DNA/RNA 
9 exons, 53 kb; alternative splicing on side of the 
transcript coding for the c-terminal part of the 
protein, leads to 6 nuclear and 1 cytoplasmic 
isoforms. 
Protein 
The PML protein is a tumor suppressor implicated in 
a wide variety of cellular activities: apoptosis, 
differentiation, genome stability. It has 3 zinc 
binding domains, BB1 (b-box1) and BB2 (b-box2) 
regions, and a coil-coiled region (CC). It contains 
also a C-terminal SUMO interaction motif (SIM) 
and 3 lysine residues able to be modified by 
SUMOylation.  
PML organises and is located in PML-nuclear bodies 
(PML-NBs) which are 0.2 to 1.0 m organelles, 
mainly located in the nucleus of many cell types. 
Their number varies from 5 to 30 per nucleus, 
according to the cell cycle and the differentiation 
stage. PML-NBs are actively involved in 
transcriptional regulation of a number of loci active 
in cell growth and differentiation. Proteins are stored 
or sequestered inside PML-NBs, until they are 
required. PML-NBs mediate protein modifications 
such as SUMOylation, acetylation, ubiquitination 
and phosphorylation (Bernardi and Pandolfi, 2007). 
RARA (Retinoic acid receptor, alpha) 
Location 
17q21.2 
Protein 
RARα protein is a member of nuclear steroid 
receptors and it presents homologies with nuclear 
receptors of vitamin D and thyroid hormone. It 
contains 2 zinc finger motifs which constitute the 
domain of linkage to the DNA (DBD, DNA binding 
domain). This link needs the formation of a 
heterodimer with the cofactor RXRα to be stable. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
t(15;17) leads to 2 fusion genes PML/RARA and 
RARA/PML. The latter is not critical; indeed it is 
lacking in 30% of cases either due to a 
submicroscopic deletion or, less frequently, to a 
mechanism of insertion. Variant or alternative 
translocations all involve RARA with another 
partner than PML; no variants are known involving 
PML with a partner different from RARA. 
Fusion protein 
Description 
The PML/RARA fusion oncoprotein is expressed in 
100% of APL cases with t(15;17) and is crucial for 
the leukemic phenotype, while RARA/PML is 
expressed in no more than 80-90% of cases and 
probably plays a secondary role.  
PML/RARA is able to homodimerise via the coiled-
coil domain of PML, forming a complex which binds 
to the DNA on RARE sites. It acts as a dominant-
negative transcriptional repressor of both target and 
non-target genes of retinoic acid. The main 
consequence is the arrest of myeloid cells 
differentiation at the promyelocytic stage. To 
achieve the gene silencing process, PML/RARA 
recruits various nuclear receptors with co-repressor 
properties, out of which RXRα, polycomb complex 
or DAXX (ZHU et al.; 2007, Lo-Coco and Hasan, 
2014). 
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